Valneva

The state of the fight: 

Oral antivirals from Pfizer and Merck notched U.S. FDA authorizations.
  Earlier use of remdesivir cut the risk of death or hospitalization by 87% in a new study.
  The Novavax vaccine secured a second WHO Emergency Use Listing.

AUTHORIZED VACCINES  

The AstraZeneca/Oxford vaccine starts waning in protection against serious illness within three months of the second dose, according to cohort studies in Brazil and Scotland published…

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses …

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 

The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.

 

AUTHORIZED VACCINES  


France and Germany recommended against the Moderna vaccine for people under 30 over concerns about…

The state of the fight: 

The Bill & Melinda Gates Foundation will invest up to $120 million to accelerate access to Merck’s molnupiravir for lower-income countries.
  Valneva’s inactivated vaccine candidate generated superior neutralizing antibody titer levels to those induced by the AstraZeneca/Oxford shot, according to a Phase 3 readout.
  U.S. regulators cleared booster shots of the J&J and Moderna vaccines and OK’d mix-and-match booster regimens. Approved or…

Pfizer enjoyed three boosts over the past week to its booming vaccine portfolio, already buoyed by global sales of Covid-19 shots.

Firstly, the company settled a patent dispute last week with Merck over their rival pneumococcal conjugate (PCV) shots. Under the settlement, Merck will pay Pfizer 7.25% of its worldwide net sales of all PCV products through the end of 2026, and 2.5% of net sales of PCV products from 2027-2035, according to Bloomberg Law.

On Tuesday, Pfizer and…

The state of the fight: 

CanSino and Pfizer/BioNTech released positive news on their respective vaccines in children.
  WHO added Regeneron and Roche’s monoclonal antibody cocktail to its list of recommended therapeutics.
  California’s NantWorks plans a $200M investment to produce Covid-19 and other vaccines in South Africa. Approved or authorized vaccines

 
Pfizer and BioNTech touted positive topline results from a Phase 2/3 trial in children ages 5-11 of…

The state of the fight: 

A U.S. regulatory committee endorsed booster doses for vulnerable people and those over age 65.
  Kenya outlined plans to start fill-finish production of Covid-19 shots in early 2022.
  An SII subsidiary scooped up a 15% stake in Biocon’s biologics unit as the companies launched a strategic alliance to produce and commercialize vaccines. Approved or authorized vaccines

 
A new substudy in The Lancet supports flexible schedules for the…

The state of the fight: 

Pfizer/BioNTech’s Comirnaty became the first Covid-19 vaccine to earn full U.S. FDA approval.
  China authorized booster doses for those at high risk of contracting Covid-19.
  Brazil’s Eurofarma Laboratórios will produce Pfizer/BioNTech’s vaccine for exclusive distribution in Latin America.

 

Approved or authorized vaccines

 
British study sees waning protection from shots: The app-based ZOE COVID study (led by a Kings College…